1. Scrip

Profile: VC Forbion's Slootweg Sees Bigger And Better European Funds

 
• By Lubna Ahmed

Sander Slootweg, managing partner and co-founder of Forbion Capital Partners, talks venture capital trends, industrial changes to watch, deal making and challenges faced during his years investing in the life science industry in the latest instalment of Scrip's executive profile series.

SANDER SLOOTWEG
Sander Slootweg, Forbion Capital Partners

Before co-founding Forbion Capital Partners as a spin-out of ABN AMRO Capital Life Sciences in 2006, Slootweg was an investment director at ABN AMRO Capital Life Sciences. As Forbion's managing partner, Slootweg played a big role in selling BioVex Inc. to Amgen Inc. in 2011 for up to $1bn and the sale of Dezima Pharma BV, also to Amgen, in 2015 for around $1.55bn. He is currently on the board of Forbion portfolio companies Xention Discovery Ltd, Pulmagen Therapeutics Ltd, Oxyrane Ltd and Replimune Ltd.

Slootweg discussed with Scrip his experience in the venture capital business, and his thoughts about the direction of biotechnology investment.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Leadership

More from Scrip

China Signals Restarting IPOs For Unprofitable Biotechs

 
• By Dexter Jie Yan

The China Securities Regulatory Commission has proposed a new “growth tier” for the STAR Market of the Shanghai Stock Exchange, to reinstate the market’s listing standards for unprofitable firms.

BIO Notebook: Woodcock Calls For Doing The Right Thing, Dealmaking Remains Constrained

 
• By Mandy Jackson, Joseph Haas, and Sarah Karlin-Smith

Highlights from Day Four of the BIO International Convention include Woodcock offering practical advice on rare disease trials, the sorry state of dealmaking mid-year, Novartis discussing its approach to partnering, and Generate looking for funding to move into Phase III.

Syncona Looks To Go Private As Market Decline Deepens

 
• By Andrew McConaghie

While some are calling for Syncona to be wound up, the UK-based company believes many existing and new investors will back the creation of new private fund.